Semaglutide
Semaglutide API
Semaglutide inogadzirwa kwenguva yakareba-inobata glucagon-sepeptide-1 (GLP-1) receptor agonist, yakagadzirirwa kurapwa kwechirwere cheshuga mellitus uye kufutisa. Yakagadziridzwa kuti irambe kukanganisa enzymatic uye kuwedzera hafu yeupenyu, Semaglutide inobvumira nyore kamwe-vhiki dosing, zvakanyanya kuvandudza kuomerera kwemurwere.
YeduSemaglutide APIinogadzirwa kuburikidza neyakagadzirwa zvizere maitiro, kubvisa njodzi dzine chekuita nebiological expression masisitimu, senge host cell protein kana kusvibiswa kweDNA. Iyo yese yekugadzira maitiro akagadziridzwa uye akasimbiswa pachiyero chekirogiramu, achizadzisa zvakaomesesa zvemhando zvinodiwa zvakatsanangurwa muFDA's 2021 nhungamiro pane ANDA kuendesa kune yakakwirira-kuchena synthetic peptide mishonga.
Nzira Yekuita
Semaglutide inotevedzera GLP-1 yemunhu, incretin hormone inoita basa rakakosha muglucose metabolism. Inoshanda kuburikidza akati wandei synergistic nzira:
-
Inokurudzira insulin secretionnenzira inoenderana neglucose
-
Inoderedza kugadzirwa kweglucagon, kuderedza kubuda kweglucose yehepatic
-
Inononoka kubuda mudumbu, zvichiita kuti pave nekuvandudzwa kwepostprandial glycemic control
-
Inoderedza kudya uye kutora simba, kutsigira kuora muviri
Clinical Migumisiro
Zvakawanda zvidzidzo zvekiriniki (semuenzaniso, iyo SUSTAIN uye STEP miedzo) yakaratidza kuti Semaglutide:
-
Zvinonyanya kudzikisa HbA1c uye kutsanya plasma mazinga eglucose mune Type 2 chirwere cheshuga
-
Inosimudzira kurasikirwa kwakanyanya uye kwakasimba muvanhu vakafuta kana vakafutisa
-
Inoderedza zviratidzo zvemoyo zvengozi seBP uye kuzvimba
Iine yakanaka kuchengetedza mbiri uye yakafara metabolic mabhenefiti, Semaglutide yave yekutanga-mutsara GLP-1 RA mune chirwere cheshuga uye anti-obesity therapy. Yedu API vhezheni inochengetedza yakakwira zvimiro kutendeseka uye yakaderera kusachena mazinga (≤0.1% isingazivikanwe kusvibiswa neHPLC), kuve nechokwadi chepamusoro chemishonga inowirirana.
